

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anderson, D.R., et al.

Serial No.: 07/978,891

Filed: November 13, 1992

Title: Therapeutic Application of
Chimeric Antibody to Human B
Lymphocyte Differentiation
Antigen for Treatment of B
Cell Lymphoma

Group Art Unit: 1805

Examiner:

COPY

March 5, 1993
La Jolla, CA

RECEIVED

APR 1 1993

GROUP 180

Honorable Commissioner of Patents and Trademarks
Box SEQUENCE
Washington, DC 20231

RESPONSE TO NOTICE TO COMPLY DATED JANUARY 11, 1993

Sir:


In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, filed simultaneously herewith are the following:

- a) Copy of Notice to Comply dated January 11, 1993;
- b) Preliminary Amendment including the changes requested in the Notice to Comply;
- c) Substitute computer readable form; and
- d) Statement pursuant to 37 C.F.R. §1.82(f).

Applicant respectfully requests a one (1) month extension in which to reply to the Notice to Comply. A check in the amount of \$55.00 is enclosed herewith; any additional funds necessary to cover the cost of this Response should be charged to our Deposit Account No. 09-0017. A copy of this sheet is enclosed.

In view of the foregoing, Applicant requests that this case be passed on for evaluation on the merits.

Respectfully submitted,



Richard P. Burgoon, Jr.
Registration No. 34,787
IDEC Pharmaceuticals Corporation
11099 North Torrey Pines Road, #160
La Jolla, CA 92037

Enc.

extraneous. Additionally, the order of the following documents is to be accorded no significance or import as the order thereof is completely fortuitous.

Copies of the documents listed on the accompanying IDS Document List (submitted in duplicate), are enclosed herewith. It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) presented on any patent which may issue in this application. Applicants respectfully request that a copy of the IDS Document List, as considered and initialed by the Examiner, be returned with the next communication.

The Office is hereby authorized to charge our Deposit Account No. 09-0017 for any fees associated with the Information Disclosure Statement. A duplicate of this sheet is enclosed.

Respectfully submitted,



Richard P. Burgoon, Jr,
Registration No. 34,787
Intellectual Property Counsel
IDEC Pharmaceuticals Corporation
11099 N. Torrey Pines Road, #160
La Jolla, CA 92037
(619) 458-0600